D. Boral Capital Reaffirms Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $5.00 price target on the stock. D. Boral Capital’s target price indicates a potential upside of 385.44% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Stock Down 5.5 %

NASDAQ HOTH traded down $0.06 on Monday, reaching $1.03. The company had a trading volume of 313,695 shares, compared to its average volume of 3,505,996. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80. The stock’s 50 day moving average is $1.22 and its 200-day moving average is $0.99. The stock has a market cap of $7.11 million, a price-to-earnings ratio of -0.78 and a beta of 0.84.

Institutional Investors Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics as of its most recent SEC filing. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.